Browsing Harvard Medical School by Keyword "adverse events"

Now showing items 1-2 of 2

    • Ipilimumab in the treatment of metastatic melanoma: management of adverse events 

      Della Vittoria Scarpati, Giuseppina; Fusciello, Celeste; Perri, Francesco; Sabbatino, Francesco; Ferrone, Soldano; Carlomagno, Chiara; Pepe, Stefano (Dove Medical Press, 2014)
      Recently, “ipilimumab,” an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. “CTLA-4” is an immune-checkpoint molecule that ...

    • PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma 

      Luke, Jason J.; Ott, Patrick A. (Impact Journals LLC, 2015)
      Checkpoint inhibitors are revolutionizing treatment options and expectations for patients with melanoma. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), was the first approved ...